Canadian company moves ahead with regenerative skin technology

11/15/2013 | Metro (Canada)

Canada-based DeCell Technologies announced plans to use an equity investment of approximately $239,000 to finish development and human testing of a product based on donated human skin that can treat diabetic foot ulcers, chronic wounds, burns and surgical wounds. When applied to wounds, the biological dressing promotes tissue regeneration.

View Full Article in:

Metro (Canada)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ